NCT04728906

Heart Patch for Myocardial Infarction COVID-19

Targeted-cell Therapy Using Epithelial Stem Cells and Patients' Cardiomyocytes Loaded in Amnion Bilayer to Regenerate Myocardial Infarction Post COVID-19 Complication

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Rumah Sakit Pusat Angkatan Darat Gatot Soebroto · Academic / Other
• Sex: All
• Age: 40 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Myocardial infarction (MI), as one of the many complications of COVID-19, is one of the contributing patients of patients' death. This study attempts on developing an intervention of MI by regenerating damaged cardiomyocytes due to insufficiency of oxygen in cardiac muscles, triggered by an occlusion of coronary artery (MI). Heart patch developed from amnion bilayer seeded with amnion epithelial stem cells and patient's autologous cardiomyocytes is used as a therapy. Patients who undergo bypass (CABG) surgery are given heart patch, and then patients condition are observed by ECG, Echo, blood test, and radiology (technetium-99m)

Conditions

• Myocardial Infarction
• Heart Diseases

Interventions

Type	Name	Description
DEVICE	Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells	heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)

Timeline

• Start date: 2022-04-01
• Primary completion: 2022-09-01
• Completion: 2022-09-01
• First posted: 2021-01-28
• Last updated: 2022-03-02

Locations

3 sites across 1 country: Indonesia